Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13

Article Oncology

Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial

Roberto Mina et al.

Summary: Maintenance treatment with carfilzomib plus lenalidomide for two years prolongs progression-free survival in patients with multiple myeloma. However, patients with two or more high-risk cytogenetic abnormalities still have an increased risk of progression and death.

LANCET ONCOLOGY (2023)

Add to Collection

Article Endocrinology & Metabolism

Increased Bone Volume by Ixazomib in Multiple Myeloma: 3-Month Results from an Open Label Phase 2 Study

Marta Diaz-delCastillo et al.

Summary: Multiple myeloma is an incurable bone marrow cancer that leads to osteolytic lesions. Treatment often involves proteasome inhibitors, but their side effects and administration route limit long-term use. This study investigates the bone effects of ixazomib, a new-generation oral proteasome inhibitor, and suggests that it may promote bone formation by reducing bone resorption and promoting longer bone formation events.

JOURNAL OF BONE AND MINERAL RESEARCH (2023)

Add to Collection

Article Oncology

Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study

Sara Bringhen et al.

Summary: This secondary analysis aimed to determine whether the PFS benefits observed in NDMM patients with maintenance ixazomib versus placebo were driven by a specific subgroup. The results showed that ixazomib prolonged PFS across all age and frailty status subgroups. It is concluded that ixazomib is a feasible and effective option for prolonging PFS in this heterogeneous patient population.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

Add to Collection

Review Oncology

Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors

Jonas Schwestermann et al.

Summary: This review article summarizes the molecular mechanisms of resistance to proteasome inhibitors in the context of the bone marrow microenvironment in patients with multiple myeloma. It also discusses the interaction between the tumor microenvironment and malignant plasma cells and its impact on metabolic changes.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Oncology